TR

Tamilselvan Ranjith

Active Director Director DIN 11912917
DIN 11912917 First appointment Aug 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Tamilselvan Ranjith

Tamilselvan Ranjith is a Director at Emediexp Private Limited (since 2026).

DIN 11912917
Primary Designation Director
First Appointment 25 Aug 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Emediexp Private Limited U47912AP2026PTC127892
Director25 Aug 20262026Active

Board colleagues of Tamilselvan Ranjith

NameDINCompanyDesignation
Alageshan Raj Kumar11912918Emediexp Private LimitedDirector
Mohankumar Balapadmasri00857619Emediexp Private LimitedIndividual Subscriber
Sridharan Gavya09093639Emediexp Private LimitedIndividual Subscriber

Directorship timeline

Open interactive timeline →
Emediexp Private Limited
Premium access

Shareholding and investment profile for Tamilselvan Ranjith

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tamilselvan Ranjith

Tamilselvan Ranjith currently holds 1 directorship: Emediexp Private Limited (Director, since 25 Aug 2026).

Tamilselvan Ranjith was first appointed on 25 Aug 2026 as Director at Emediexp Private Limited.

The current boards of Tamilselvan Ranjith's companies include Alageshan Raj Kumar (Emediexp Private Limited), Mohankumar Balapadmasri (Emediexp Private Limited), Sridharan Gavya (Emediexp Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available